Label: HALAVEN- eribulin mesylate injection

  • NDC Code(s): 43624-002-01
  • Packager: BSP Pharmaceuticals SpA
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Drug Application

Drug Label Information

Updated November 22, 2023

If you are a consumer or patient please visit this version.

View All Sections
  • Halaven®

    (eribulin mesylate) Injection, for intravenous use
    1 mg/2 mL (0.5 mg/mL)

  • PRINCIPAL DISPLAY PANEL - SHIPPER LABEL

    Eisai Manufacturing Limited                

    ​Allegato DQA-035/XXXX​

    New Chemical Entity Demand Chain Unit European Knowledge Centre

    Mosquito Way-Hatfield, Herts, AL 109SN

    United Kingdom

    ​​ HALAVEN®
    (eribulin mesylate) Injection, for intravenous use- 0.5mg/ml, 2 ml
    Store at 15° - 25°C (59° - 77°F). DO NOT FREEZE

    QTY: 00XXX EXP: MM-YYYY LOT: F1XXYZZZ
     (22) 900XXX MMYYYY F1XXYZZZ 7

    NDC 43624-002-01

    (0X) 50X XXXXX 00X X X0 XXX

    Manufactured by : BSP Pharmaceuticals SpA-Latina Scalo, Italy.

    ​

    Image (eribulin mesylate) Injection1 mg/2 mL(0.5 mg/mL)For Intravenous Use

  • INGREDIENTS AND APPEARANCE
    HALAVEN 
    eribulin mesylate injection
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:43624-002
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    ERIBULIN MESYLATE (UNII: AV9U0660CW) (ERIBULIN - UNII:LR24G6354G) ERIBULIN MESYLATE0.5 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    ALCOHOL (UNII: 3K9958V90M)  
    WATER (UNII: 059QF0KO0R)  
    Product Characteristics
    Colorwhite (clear, colorless, sterile solution for intravenous administration) Score    
    ShapeSize
    FlavorImprint Code
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:43624-002-01100 in 1 BOX, UNIT-DOSE04/21/2017
    13 mL in 1 TRAY; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA20153204/21/2017
    Labeler - BSP Pharmaceuticals SpA (857007830)
    Registrant - BSP Pharmaceuticals SpA (857007830)
    Establishment
    NameAddressID/FEIBusiness Operations
    BSP Pharmaceuticals SpA857007830manufacture(43624-002)
View All Sections

Find additional resources

(also available in the left menu)

Safety

Report Adverse Events, FDA Safety Recalls, Presence in Breast Milk

Related Resources

Medline Plus, Clinical Trials, PubMed, Biochemical Data Summary

More Info on this Drug

View Labeling Archives, RxNorm, Get Label RSS Feed, View NDC Code(s)NEW!